Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
Location: United States
Total raised: $141M
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.04.2026 | Series B | $100M | Janus Hend... |
| 11.12.2024 | Series A | $25M | - |
| 21.08.2024 | Series A | $16M | - |
Mentions in press and media 10
| Date | Title | Description |
| 03.04.2026 | Ambrosia Biosciences Fuels Next-Gen Oral Metabolic Drug Development | Ambrosia Biosciences secured a monumental $100 million Series B funding. This capital injection immediately accelerates their oral small molecule GLP-1 candidate into pivotal clinical trials. It also vigorously advances their broader pipeli... |
| 01.04.2026 | Ambrosia Biosciences: $100 Million Raised For Cardiometabolic Small Molecule Pipeline Advancement | Ambrosia Biosciences announced that it has raised $100 million in an oversubscribed Series B financing round to advance its pipeline of orally delivered small molecule therapies targeting cardiometabolic diseases. The financing was co-led b... |
| 31.03.2026 | Ambrosia Biosciences Raises $100M in Series B Funding | Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $100M in Series B funding. The round was led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, with participation from existing investors BVF Partn... |
| 19.02.2025 | Ambrosia Biosciences Further Strengthens Board of Directors with Appointment of Jason Haddock | logo Mr. Haddock brings more than 25 years of financial and operational experience as Ambrosia advances preclinical pipeline BOULDER, Colo., Feb. 19, 2025 /PRNewswire-PRWeb/ -- Ambrosia Biosciences Inc. ("Ambrosia"), today announc... |
| 11.12.2024 | Ambrosia Biosciences Raises $25M in Series A Financing | Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $25M in Series A funding. The round was led by Merck with participation from participation from existing investors BVF Partners and Boulder Ventures. The company inten... |
| 10.12.2024 | Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by Merck | Ambrosia Biosciences announces a second closing of its Series A financing. This closing was led by Merck with additional participation from existing investors. This financing will further expand preclinical development operations in our fac... |
| 21.08.2024 | Business | Ambrosia Biosciences launches with $16M investment, Array chemistry team | Ambrosia Biosciences Inc., a recently formed drug-discovery company, has raised a $16 million Series A round and reunited a team of scientists that previously worked for Pfizer Inc.’s (NYSE: PFE) now-shuttered Boulder research and developme... |
| 21.08.2024 | Ambrosia Biosciences Raises $16M Series A Financing | Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $16M in Series A funding. The round wads led by BVF Partners and Boulder Ventures. Ambrosia Biosciences is a drug discovery company developing orally delivered, small ... |
| 20.08.2024 | Ambrosia Biosciences announces $16MM Series A Financing | Ambrosia Biosciences announces the closing of our Series A financing. Led by BVF Partners and Boulder Ventures, this funding will allow us to launch operations in Boulder, CO and fuel our exceptional drug discovery team. Initiates Small Mol... |
| - | Ambrosia Biosciences | “Ambrosia Biosciences” |